About dbv technologies - DBVT
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients. It also designs a robust clinical development program that includes ongoing clinical trials of Viaskin peanut, and Viaskin milk, as well as pre-clinical development of Viaskin egg. The company was founded by Pierre-Henri Benhamou, Stéphane Benhamou, Bertrand Dupont, Christophe Dupont, and Pierre-Yves Vannerom on March 29, 2002 and is headquartered in Chatillon, France.
DBVT At a Glance
DBV Technologies SA
107 avenue de la Republique
Chatillon, Hauts-de-France 92320
| Phone | 33-1-55-42-78-78 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -113,716,769.16 | |
| Sector | Health Technology | Employees | 109 | |
| Fiscal Year-end | 12 / 2025 | |||
| View SEC Filings |
DBVT Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.235 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.356 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.372 |
DBVT Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -1,043,273.112 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
DBVT Liquidity
| Current Ratio | 1.426 |
| Quick Ratio | 1.426 |
| Cash Ratio | 1.042 |
DBVT Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -91.47 |
| Return on Equity | -135.722 |
| Return on Total Capital | -267.707 |
| Return on Invested Capital | -127.488 |
DBVT Capital Structure
| Total Debt to Total Equity | 55.103 |
| Total Debt to Total Capital | 35.527 |
| Total Debt to Total Assets | 22.984 |
| Long-Term Debt to Equity | 22.993 |
| Long-Term Debt to Total Capital | 14.824 |